StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$3.02+0.14 (+4.86%)

Close on Nov 18, 2026Market cap $243.33MP/E 13.1Yield –

Protalix BioTherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Protalix BioTherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $7.67M. For fiscal 2025 it was -$13.63M, down 284.4% from the year before. The highest annual figure on record is $38.26M in fiscal 2009.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.63M-284.4%
FY2024Dec 31, 2024$7.39M–
FY2023Dec 31, 2023-$2.47M–
FY2022Dec 31, 2022-$25.63M–
FY2021Dec 31, 2021-$11.74M–
FY2020Dec 31, 2020-$26.76M–
FY2019Dec 31, 2019-$19.99M–
FY2018Dec 31, 2018-$8.43M–
FY2017Dec 31, 2017-$10.97M–
FY2016Dec 31, 2016-$32.95M–
FY2015Dec 31, 2015-$24.75M–
FY2014Dec 31, 2014-$30.07M–
FY2013Dec 31, 2013-$32.54M–
FY2012Dec 31, 2012-$1.43M–
FY2011Dec 31, 2011-$29.28M–
FY2010Dec 31, 2010-$46.32M-221.1%
FY2009Dec 31, 2009$38.26M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.99M–
Q1 FY2026Mar 31, 2026$21.26M–
Q4 FY2025Dec 31, 2025$1.63M-54.4%
Q3 FY2025Sep 30, 2025-$4.23M-205.3%
Q2 FY2025Jun 30, 2025-$5.66M–
Q1 FY2025Mar 31, 2025-$5.36M-249.4%
Q4 FY2024Dec 31, 2024$3.57M+6.6%
Q3 FY2024Sep 30, 2024$4.02M–
Q2 FY2024Jun 30, 2024-$3.78M-179.3%
Q1 FY2024Mar 31, 2024$3.59M–
Q4 FY2023Dec 31, 2023$3.35M–
Q3 FY2023Sep 30, 2023-$7.34M–
Q2 FY2023Jun 30, 2023$4.77M–
Q1 FY2023Mar 31, 2023-$3.25M–
Q4 FY2022Dec 31, 2022-$2.82M–
Q3 FY2022Sep 30, 2022-$9.26M–
Q2 FY2022Jun 30, 2022-$7.48M-220.0%
Q1 FY2022Mar 31, 2022-$6.06M–
Q4 FY2021Dec 31, 2021-$5.54M–
Q3 FY2021Sep 30, 2021-$2.22M–
Q2 FY2021Jun 30, 2021$6.24M–
Q1 FY2021Mar 31, 2021-$10.22M–
Q4 FY2020Dec 31, 2020-$7.83M–
Q1 FY2020Mar 31, 2020-$7.18M–
Q4 FY2019Dec 31, 2019-$3.72M–
Q3 FY2019Sep 30, 2019-$3.62M-126.7%
Q2 FY2019Jun 30, 2019-$5.21M–
Q1 FY2019Mar 31, 2019-$7.45M–
Q4 FY2018Dec 31, 2018-$4.19M-124.2%
Q3 FY2018Sep 30, 2018$13.54M–
Q2 FY2018Jun 30, 2018-$8.11M–
Q1 FY2018Mar 31, 2018-$9.66M–
Q4 FY2017Dec 31, 2017$17.30M–
Q3 FY2017Sep 30, 2017-$10.68M–
Q2 FY2017Jun 30, 2017-$8.94M–
Q1 FY2017Mar 31, 2017-$8.65M–
Q4 FY2016Dec 31, 2016-$7.46M–
Q3 FY2016Sep 30, 2016-$3.60M–
Q2 FY2016Jun 30, 2016-$12.02M–

More Protalix BioTherapeutics figures

See a number that looks wrong?